FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213638408> ?p ?o ?g. }

• W3213638408 endingPage "41" @default.
• W3213638408 startingPage "41" @default.
• W3213638408 abstract "In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making for men aged 55 to 69 years (grade C).To evaluate changes in rates of PSA testing after revisions in the USPSTF guideline on prostate cancer screening.This retrospective cohort study used deidentified claims data from Blue Cross Blue Shield beneficiaries aged 40 to 89 years from January 1, 2013, through December 31, 2019.Publication of the USPSTF's draft (April 2017) and final (May 2018) recommendation on prostate cancer screening.Age-adjusted rates of PSA testing in bimonthly periods were calculated, and PSA testing rates from calendar years before (January 1 to December 31, 2016) and after (January 1 to December 31, 2019) the guideline change were compared. Interrupted time series analyses were used to evaluate the association of the draft (April 2017) and published (May 2018) USPSTF guideline with rates of PSA testing. Changes in rates of PSA testing were further evaluated among beneficiaries within the age categories reflected in the guideline: 40 to 54 years, 55 to 69 years, and 70 to 89 years.The median number of eligible beneficiaries for each bimonthly period was 8 087 565 (range, 6 407 602-8 747 308), and the median age of all included eligible beneficiaries was 53 years (IQR, 47-59 years). Between 2016 and 2019, the mean (SD) rate of PSA testing increased from 32.5 (1.1) to 36.5 (1.1) tests per 100 person-years, a relative increase of 12.5% (95% CI, 1.1%-24.4%). During the same period, mean (SD) rates of PSA testing increased from 20.6 (0.8) to 22.7 (0.9) tests per 100 person-years among men aged 40 to 54 years (relative increase, 10.1%; 95% CI, -2.8% to 23.7%), from 49.8 (1.9) to 55.8 (1.8) tests per 100 person-years among men aged 55 to 69 years (relative increase, 12.1%; 95% CI, -0.2% to 25.2%), and from 38.0 (1.4) to 44.2 (1.4) tests per 100 person-years among men aged 70 to 89 years (relative increase, 16.2%; 95% CI, 4.2%-29.0%). Interrupted time series analysis revealed a significantly increasing trend of PSA testing after April 2017 among all beneficiaries (0.30 tests per 100 person-years for each bimonthly period; P < .001).This large national cohort study found that rates of PSA testing increased after the USPSTF's draft statement in 2017, reversing trends seen after earlier guidance against PSA testing for all patients. Increased testing was also observed among older men, who may be less likely to benefit from prostate cancer screening." @default.
• W3213638408 created "2021-11-22" @default.
• W3213638408 creator A5004483141 @default.
• W3213638408 creator A5061395570 @default.
• W3213638408 creator A5065455532 @default.
• W3213638408 creator A5078274522 @default.
• W3213638408 creator A5078289544 @default.
• W3213638408 creator A5081831577 @default.
• W3213638408 creator A5086007942 @default.
• W3213638408 creator A5090259653 @default.
• W3213638408 date "2022-01-01" @default.
• W3213638408 modified "2023-09-25" @default.
• W3213638408 title "Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening" @default.
• W3213638408 cites W2008421511 @default.
• W3213638408 cites W2032038249 @default.
• W3213638408 cites W2068376654 @default.
• W3213638408 cites W2110228583 @default.
• W3213638408 cites W2120357482 @default.
• W3213638408 cites W2134793522 @default.
• W3213638408 cites W2157123352 @default.
• W3213638408 cites W2175023894 @default.
• W3213638408 cites W2300993928 @default.
• W3213638408 cites W2313383114 @default.
• W3213638408 cites W2440538944 @default.
• W3213638408 cites W2513507045 @default.
• W3213638408 cites W2577453388 @default.
• W3213638408 cites W2791546899 @default.
• W3213638408 cites W2793905111 @default.
• W3213638408 cites W2801556653 @default.
• W3213638408 cites W2808315545 @default.
• W3213638408 cites W2808933803 @default.
• W3213638408 cites W2887335957 @default.
• W3213638408 cites W2904493400 @default.
• W3213638408 cites W2966258052 @default.
• W3213638408 cites W2980970087 @default.
• W3213638408 cites W3010331388 @default.
• W3213638408 cites W3036734356 @default.
• W3213638408 cites W3049211590 @default.
• W3213638408 cites W3083957268 @default.
• W3213638408 cites W3097328392 @default.
• W3213638408 cites W3118917667 @default.
• W3213638408 cites W3152237564 @default.
• W3213638408 cites W4230644069 @default.
• W3213638408 cites W4235530406 @default.
• W3213638408 cites W4245607349 @default.
• W3213638408 cites W4247851958 @default.
• W3213638408 cites W603598610 @default.
• W3213638408 cites W2991985179 @default.
• W3213638408 doi "https://doi.org/10.1001/jamaoncol.2021.5143" @default.
• W3213638408 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8587214" @default.
• W3213638408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34762100" @default.
• W3213638408 hasPublicationYear "2022" @default.
• W3213638408 type Work @default.
• W3213638408 sameAs 3213638408 @default.
• W3213638408 citedByCount "18" @default.
• W3213638408 countsByYear W32136384082022 @default.
• W3213638408 countsByYear W32136384082023 @default.
• W3213638408 crossrefType "journal-article" @default.
• W3213638408 hasAuthorship W3213638408A5004483141 @default.
• W3213638408 hasAuthorship W3213638408A5061395570 @default.
• W3213638408 hasAuthorship W3213638408A5065455532 @default.
• W3213638408 hasAuthorship W3213638408A5078274522 @default.
• W3213638408 hasAuthorship W3213638408A5078289544 @default.
• W3213638408 hasAuthorship W3213638408A5081831577 @default.
• W3213638408 hasAuthorship W3213638408A5086007942 @default.
• W3213638408 hasAuthorship W3213638408A5090259653 @default.
• W3213638408 hasBestOaLocation W32136384082 @default.
• W3213638408 hasConcept C121608353 @default.
• W3213638408 hasConcept C126322002 @default.
• W3213638408 hasConcept C142724271 @default.
• W3213638408 hasConcept C167135981 @default.
• W3213638408 hasConcept C2775941076 @default.
• W3213638408 hasConcept C2780182762 @default.
• W3213638408 hasConcept C2780192828 @default.
• W3213638408 hasConcept C2781406297 @default.
• W3213638408 hasConcept C29456083 @default.
• W3213638408 hasConcept C71924100 @default.
• W3213638408 hasConcept C72563966 @default.
• W3213638408 hasConceptScore W3213638408C121608353 @default.
• W3213638408 hasConceptScore W3213638408C126322002 @default.
• W3213638408 hasConceptScore W3213638408C142724271 @default.
• W3213638408 hasConceptScore W3213638408C167135981 @default.
• W3213638408 hasConceptScore W3213638408C2775941076 @default.
• W3213638408 hasConceptScore W3213638408C2780182762 @default.
• W3213638408 hasConceptScore W3213638408C2780192828 @default.
• W3213638408 hasConceptScore W3213638408C2781406297 @default.
• W3213638408 hasConceptScore W3213638408C29456083 @default.
• W3213638408 hasConceptScore W3213638408C71924100 @default.
• W3213638408 hasConceptScore W3213638408C72563966 @default.
• W3213638408 hasIssue "1" @default.
• W3213638408 hasLocation W32136384081 @default.
• W3213638408 hasLocation W32136384082 @default.
• W3213638408 hasLocation W32136384083 @default.
• W3213638408 hasOpenAccess W3213638408 @default.
• W3213638408 hasPrimaryLocation W32136384081 @default.
• W3213638408 hasRelatedWork W1911010690 @default.
• W3213638408 hasRelatedWork W1966688579 @default.
• W3213638408 hasRelatedWork W2002790620 @default.

• next